Decreased α-synuclein expression in the aging mouse substantia nigra

Experimental Neurology

Volumn 220, Issue 2, 2009, Pages 359-365

  Mak, Sally K ^a   McCormack, Alison L ^a   Langston, J William ^a   Kordower, Jeffrey H ^b   Di Monte, Donato A ^a  

^a PARKINSON S INSTITUTE   (United States)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Synuclein; Age; Dopaminergic neurons; Hippocampus; Immunohistochemistry; Mice; Parkinson; RNA; Synaptic plasticity; Synuclein

Indexed keywords

ALPHA SYNUCLEIN; BETA SYNUCLEIN; MESSENGER RNA;

AGE; AGING; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; HIPPOCAMPUS; MALE; MESENCEPHALON; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SUBSTANTIA NIGRA;

AGING; ALPHA-SYNUCLEIN; ANIMALS; DOPAMINE; HIPPOCAMPUS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MALE; MICE; MICE, INBRED C57BL; NEURONS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SUBSTANTIA NIGRA; TYROSINE 3-MONOOXYGENASE;

EID: 71549167611     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2009.09.021     Document Type: Article

References (25)

1. Abeliovich A., Schmitz Y., Farinas I., Choi-Lundberg D., Ho W.H., Castillo P.E., Shinsky N., Verdugo J.M., Armanini M., Ryan A., Hynes M., Phillips H., Sulzer D., and Rosenthal A. Mice lacking α-synuclein display functional deficits in the nigrostriatal dopamine system. Neuron 25 (2000) 239-252
2. Adamczyk A., Solecka J., and Strosznajder J.B. Expression of α-synuclein in different brain parts of adult and aged rats. J. Physiol. Pharmacol. 56 (2005) 29-37
3. Al-Wandi, A., Ninkina, N., Millership, S., Williamson, S.J., Jones, P.A., Buchman, V.L., in press. Absence of α-synuclein affects dopamine metabolism and synaptic markers in the striatum of aging mice. Neurobiol. Aging.10.1016/j.neurobiolaging.2008.11.001
4. Chu Y., and Kordower J.H. Age-associated increases of α-synuclein in monkeys and humans are associated with nigrostriatal dopamine depletion: is this the target for Parkinson's disease?. Neurobiol. Dis. 25 (2007) 134-149
5. Clayton D.F., and George J.M. The synucleins: a family of proteins involved in synaptic function, plasticity, neurodegeneration and disease. Trends Neurosci. 21 (1998) 249-254
6. Conway K.A., Rochet J.C., Bieganski R.M., and Lansbury P.T. Kinetic stabilization of the α-synuclein protofibril by a dopamine-α-synuclein adduct. Science 294 (2001) 1346-1349
7. Eslamboli A., Romero-Ramos M., Burger C., Björklund T., Muzyczka N., Mandel R.J., Baker H., Ridley R.M., and Kirik D. Long-term consequences of human α-synuclein overexpression in the primate ventral midbrain. Brain 130 (2007) 799-815
8. Farrer M., Kachergus J., Forno L., Lincoln S., Wang D.S., Hulihan M., Maraganore D., Gwinn-Hardy K., Wszolek Z., Dickson D., and Langston J.W. Comparison of kindreds with parkinsonism and α-synuclein genomic multiplications. Ann. Neurol. 55 (2004) 174-179
9. Hamilton B.A. α-Synuclein A53T substitution associated with Parkinson's disease also marks the divergence of Old World and New World primates. Genomics 83 (2004) 739-742
10. Irwin I., Finnegan K.T., DeLanney L.E., Di Monte D., and Langston J.W. The relationships between aging, monoamine oxidase, striatal dopamine and the effects of MPTP in C57BL/6 mice: a critical reassessment. Brain Res. 572 (1992) 224-231
11. Kruger R., Kuhn W., Muller T., Woitalla D., Graeber M., Kosel S., Przuntek H., Eppelen J.T., Schols L., and Reiss O. Ala30Pro mutation in the gene encoding α-synuclein in Parkinson's disease. Nat. Genet. 18 (1998) 106-108
12. Li W., Lesuisse C., Xu Y., Troncoso J.C., Price D.L., and Lee M.K. Stabilization of α-synuclein protein with aging and familial Parkinson's disease-linked A53T mutation. J. Neurosci. 24 (2004) 7400-7409
13. Malatynska E., Pinhasov A., Crooke J., Horowitz D., Brenneman D.E., and Ilyin S.E. Levels of mRNA coding for α-, β-, and γ-synuclein in the brains of newborn, juvenile and adult rats. J. Mol. Neurosci. 29 (2006) 269-277
14. Martinez-Vicente M., Talloczy Z., Kaushik S., Massey A.A., Mazzulli J., Mosharov E.V., Hodara R., Fredenburg R., Wu D.C., Follenzi A., Dauer W., Przedborski S., Ischiropoulos H., Lansbury P.T., Sulzer D., and Cuervo A.M. Dopamine-modified α-synuclein blocks chaperone-mediated autophagy. J. Clin. Invest. 118 (2008) 777-788
15. Massey A.C., Kaushik S., Sovak G., Kiffin R., and Cuervo A.M. Consequences of the selective blockage of chaperone-mediated autophagy. Proc. Natl. Acad. Sci. U.S.A. 103 (2006) 5805-5810
16. McCormack A.L., and Di Monte D.A. Enhanced α-synuclein expression in human neurodegenerative diseases: pathogenetic and therapeutic implications. Curr. Protein Pept. Sci. 10 (2009) 476-482
17. McCormack A.L., Di Monte D.A., Delfani K., Irwin I., DeLanney L.E., Langston W.J., and Janson A.A. Aging of the nigrostriatal system in the squirrel monkey. J. Comp. Neurol. 471 (2004) 387-395
18. Petersen K., Olesen O.F., and Mikkelsen J.D. Developmental expression of α-synuclein in rat hippocampus and cerebral cortex. Neuroscience 91 (1999) 651-659
19. Polymeropoulos M.H., Lavedan C., Leroy E., Ide S.E., Dehejia A., Dutra A., Pike B., Root H., Rubenstein J., Boyer R., Stenroos E.S., Chandrasekharappa S., Athanassiadou A., Papapetropoulos T., Johnston W.G., Lazzarini A.M., Duvoisin R.C., Di Iorio G., Golbi L.I., and Nussbaum R.L. Mutation in the α-synuclein gene identified in families with Parkinson's disease. Science 276 (1997) 2045-2047
20. Purisai M.G., McCormack A.L., Langston W.J., Johnston L.C., and Di Monte D.A. α-Synuclein expression in the substantia nigra of MPTP-lesioned non-human primates. Neurobiol. Dis. 20 (2005) 898-906
21. Singleton A.B., Farrer M., Johnson J., Singleton A., Hague S., Kachergus J., Hulihan M., Peuralinna T., Dutra A., Nussbaum R., Lincoln S., Crawley A., Hanson M., Maraganore D., Adler C., Cookson M.R., Muenter M., Baptista M., Miller D., Blancato J., Hardy J., and Gwinn-Hardy K. α-Synuclein locus triplication causes Parkinson's disease. Science 302 (2003) 841
22. Spillantini M.G., Crowther R.A., Jakes R., Hasegawa M., and Goerdert M. α-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with Lewy bodies. Proc. Natl. Acad. Sci. U.S.A. 95 (1998) 6469-6473
23. Thiruchelvam M., McCormack A., Richfield E.K., Baggs R.B., Tank A.W., Di Monte D.A., and Cory-Slechta D.A. Age-related irreversible progressive nigrostriatal dopaminergic neurotoxicity in the paraquat and maneb model of the Parkinson's disease phenotype. Eur. J. Neurosci. 18 (2003) 589-600
24. Tu P.H., Galvin J.E., Baba M., Giasson B., Tomita T., Leight S., Nakajo S., Iwatsubo T., Trojanowski J.Q., and Lee V.M. Glial cytoplasmic inclusions in white matter oligodendrocytes of multiple system atrophy brains contain insoluble α-synuclein. Ann. Neurol. 44 (1998) 415-422
25. Zarranz J.J., Alegre J., Gomez-Esteban J.C., Lezcano E., Ros R., Ampuero I., Vidal L., Hoenicka J., Rodríguez O., Atares B., Llorens V., Gomez Tortosa E., del Ser T., Munoz D.G., and de Yerbenes J.G. The new mutation, E46K, of α-synuclein causes Parkinson and Lewy body dementia. Ann. Neurol. 55 (2004) 164-173